Skip to main content

Table 1 Body weight and biochemical parameters on day 21 in NASH mice under diabetic background (vehicle, lina 10 mg/Kg, Empa 10 mg/Kg, and Lina+Empa) and their normal littermates

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

  Control (n = 6) Vehicle (n = 6) Lina 10 mg/Kg (n = 6) Empa 10 mg/Kg (n = 6) Lina + empa (n = 6)
Body weight (g)
 Day 0 22.6 ± 0.2 20.0 ± 0.9 19.9 ± 0.9 20.3 ± 1.2 20.5 ± 1.0
 Day 21 25.1 ± 0.5 21.9 ± 0.7 21.6 ± 0.9* 21.8 ± 1.2 22.8 ± 0.6
Plasma glucose (mg/dl) 184.5 ± 14.1 470.7 ± 53.7 479.0 ± 49.2 319.3 ± 35.1 345.0 ± 57.6
GA (%) 2.35 ± 0.36 5.86 ± 0.73* 5.53 ± 0.43* 2.58 ± 0.50§, # 3.32 ± 0.44
ALT (U/l) 28.3 ± 3.7 42.8 ± 5.7 52.5 ± 15.9 20.7 ± 4.0§ 23.8 ± 2.3
Triglyceride (mg/dl) 40.8 ± 5.3 36.8 ± 7.8 37.3 ± 7.3 26.0 ± 6.3 43.2 ± 8.4
Free fatty acid (mEq/l) 0.76 ± 0.06 1.72 ± 0.15 1.80 ± 0.29 2.02 ± 0.21 2.10 ± 0.06
Insulin (ng/ml) 0.53 ± 0.05 0.40 ± 0.07 0.69 ± 0.19 0.79 ± 0.06 0.92 ± 0.18§
  1. Data are mean ± SE
  2. Lina linagliptin; Empa empagliflozin; GA glycated albumin; ALT alanine aminotransferase
  3. * P < 0.05,  P < 0.01,  P < 0.001 vs. control; § P < 0.05, || P < 0.01,  P < 0.001 vs. vehicle; # P < 0.05, ** P < 0.01, †† P < 0.001 vs. linagliptin alone